Scholarlink

Background <p>Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abnormal brain-gut interactions. The pathogenic mechanisms of IBS are not fully understood, and current treatments are limited in efficacy.</p> Aims <p>This study aims to investigate the potential therapeutic effects of mesenchymal stem cell-derived apoptotic vesicles (apoVs) on IBS in a mouse model, focusing on their impact on the 5-HT brain-gut axis.</p> Methods <p>We extracted and characterized apoVs from adipose-derived stem cells (ADSCs, Mesenchymal stem cells derived from adipose) induced to undergo apoptosis. IBS was induced in C57BL/6 mice using a chronic stress model. Mice were treated with apoVs via tail vein injection, and various behavioral, physiological, and biochemical parameters were assessed. </p> Results <p>IBS patients exhibited increased circulating vesicles in peripheral blood, correlating with brain functional activity. Further animal studies found that apoVs treatment in IBS mice reduced 5-HT levels in the brain and gut, alleviated symptoms such as slowed weight gain and visceral hypersensitivity, and restored intestinal barrier function. Additionally, apoVs improved neuronal activation and mucin secretion in the gut.</p> Conclusions <p>Our findings suggest that apoVs act as novel messengers in brain-gut axis interactions, regulating brain-gut homeostasis. This study provides a new therapeutic approach for the treatment of functional gastrointestinal disorders like IBS.</p> Graphical abstract <p>Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abnormal brain-gut interactions, with unclear pathogenic mechanisms and no curative treatments currently available. In this study, we observed an increased number of circulating vesicles in peripheral blood samples from IBS patients compared to healthy controls, which correlated with brain functional activity. Administration of MSC-derived apoptotic vesicles (apoVs) via tail vein injection in IBS mice reduced 5-HT levels in both the brain and gut, modulating the brain-gut axis signaling. This treatment alleviated symptoms such as slowed weight gain, visceral hypersensitivity, and decreased serum diamine oxidase levels, while restoring intestinal barrier function. Additionally, the apoVs treatment group exhibited significant improvements in neuronal activation and mucin secretion in the gut. Our findings suggest that apoVs act as novel messengers in brain-gut axis interactions, regulating brain-gut homeostasis and providing a new therapeutic approach for the treatment of functional gastrointestinal disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal stem cell-derived apoptotic vesicles regulate irritable bowel syndrome in mice via the 5-HT brain-gut axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Ya Sun,
  • Di Wu,
  • Lu Lu,
  • Jinyang Wang,
  • Xuanyi Li,
  • Xueli Mao,
  • Yijun Zhang

摘要

Background

Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abnormal brain-gut interactions. The pathogenic mechanisms of IBS are not fully understood, and current treatments are limited in efficacy.

Aims

This study aims to investigate the potential therapeutic effects of mesenchymal stem cell-derived apoptotic vesicles (apoVs) on IBS in a mouse model, focusing on their impact on the 5-HT brain-gut axis.

Methods

We extracted and characterized apoVs from adipose-derived stem cells (ADSCs, Mesenchymal stem cells derived from adipose) induced to undergo apoptosis. IBS was induced in C57BL/6 mice using a chronic stress model. Mice were treated with apoVs via tail vein injection, and various behavioral, physiological, and biochemical parameters were assessed.

Results

IBS patients exhibited increased circulating vesicles in peripheral blood, correlating with brain functional activity. Further animal studies found that apoVs treatment in IBS mice reduced 5-HT levels in the brain and gut, alleviated symptoms such as slowed weight gain and visceral hypersensitivity, and restored intestinal barrier function. Additionally, apoVs improved neuronal activation and mucin secretion in the gut.

Conclusions

Our findings suggest that apoVs act as novel messengers in brain-gut axis interactions, regulating brain-gut homeostasis. This study provides a new therapeutic approach for the treatment of functional gastrointestinal disorders like IBS.

Graphical abstract

Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abnormal brain-gut interactions, with unclear pathogenic mechanisms and no curative treatments currently available. In this study, we observed an increased number of circulating vesicles in peripheral blood samples from IBS patients compared to healthy controls, which correlated with brain functional activity. Administration of MSC-derived apoptotic vesicles (apoVs) via tail vein injection in IBS mice reduced 5-HT levels in both the brain and gut, modulating the brain-gut axis signaling. This treatment alleviated symptoms such as slowed weight gain, visceral hypersensitivity, and decreased serum diamine oxidase levels, while restoring intestinal barrier function. Additionally, the apoVs treatment group exhibited significant improvements in neuronal activation and mucin secretion in the gut. Our findings suggest that apoVs act as novel messengers in brain-gut axis interactions, regulating brain-gut homeostasis and providing a new therapeutic approach for the treatment of functional gastrointestinal disorders.